---
layout: default
title: Cephalexin
description: "Cephalexin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 44
evidence_level: L5
indication_count: 0
---

# Cephalexin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>0</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Cephalexinï¼šç¶“å…¸ç¬¬ä¸€ä»£é ­å­¢é»´ç´ çš„è©•ä¼°

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Cephalexin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Cephalexin æ˜¯ç¬¬ä¸€ä»£é ­å­¢é»´ç´ é¡å£æœæŠ—ç”Ÿç´ ï¼Œå»£æ³›ç”¨æ–¼æ²»ç™‚ç´°èŒæ„ŸæŸ“ã€‚
ç›®å‰**ç„¡æ–°é©æ‡‰ç—‡é æ¸¬**ï¼Œæ‡‰ç¹¼çºŒåœ¨æ ¸å‡†é©æ‡‰ç—‡ç¯„åœå…§ä½¿ç”¨ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è‘¡è„çƒèŒã€éˆçƒèŒã€è‚ºç‚é›™çƒèŒã€è…¦è†œç‚çƒèŒåŠå…¶ä»–å…·æœ‰æ„Ÿå—æ€§ç´°èŒå¼•èµ·ä¹‹æ„ŸæŸ“ç—‡ï¼ˆå‘¼å¸é“ã€æ³Œå°¿é“ã€çš®è†šè»Ÿçµ„ç¹”ã€éª¨é—œç¯€ç­‰ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ |  |
| TxGNN é æ¸¬åˆ†æ•¸ | ç„¡ |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 313 å¼µï¼ˆå«å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Hold |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Cephalexin æ˜¯ä¸€ç¨®ç¶“å…¸çš„ç¬¬ä¸€ä»£é ­å­¢é»´ç´ é¡æŠ—ç”Ÿç´ ï¼Œå…¶ç‰¹æ€§åŒ…æ‹¬ï¼š

1. **ä½œç”¨æ©Ÿè½‰**ï¼šæŠ‘åˆ¶ç´°èŒç´°èƒå£è‚½èšç³–åˆæˆï¼Œå°é©è˜­æ°é™½æ€§èŒæ´»æ€§è¼ƒå¼·
2. **è—¥ç‰©å‹•åŠ›å­¸**ï¼šå£æœå¸æ”¶è‰¯å¥½ï¼Œä¸»è¦ç¶“è…è‡Ÿæ’æ³„
3. **è‡¨åºŠå®šä½**ï¼šå¸¸ç”¨æ–¼è¼•ä¸­åº¦çš®è†šè»Ÿçµ„ç¹”æ„ŸæŸ“ã€æ³Œå°¿é“æ„ŸæŸ“ã€å‘¼å¸é“æ„ŸæŸ“

ç”±æ–¼ TxGNN æ¨¡å‹æœªé æ¸¬åˆ°æ–°é©æ‡‰ç—‡ï¼Œé€™å¯èƒ½è¡¨ç¤ºï¼š
- Cephalexin çš„è—¥ç†ç‰¹æ€§è¼ƒç‚ºå°ˆä¸€ï¼Œä¸»è¦é™æ–¼æŠ—èŒä½œç”¨
- çŸ¥è­˜åœ–è­œä¸­æœªç™¼ç¾èˆ‡å…¶ä»–ç–¾ç—…çš„é¡¯è‘—é—œè¯
- è©²è—¥ç‰©åœ¨å…¶æ ¸å‡†ç”¨é€”ä¸Šå·²è¢«å……åˆ†ç ”ç©¶å’Œä½¿ç”¨

## è‡¨åºŠè©¦é©—è­‰æ“š

ç„¡æ–°é©æ‡‰ç—‡ç›¸é—œè‡¨åºŠè©¦é©—ã€‚

## æ–‡ç»è­‰æ“š

ç„¡æ–°é©æ‡‰ç—‡ç›¸é—œæ–‡ç»ã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è£½å­—ç¬¬058146è™Ÿ | "ä¿¡æ±"ä¿¡ä¿æ¬£ä¹¾ç²‰æ³¨å°„åŠ‘1å…¬å…‹ | ä¹¾ç²‰æ³¨å°„åŠ‘ | è‘¡è„çƒèŒã€éˆçƒèŒã€è‚ºç‚é›™çƒèŒã€è…¦è†œç‚çƒèŒåŠå…¶ä»–å…·æœ‰æ„Ÿå—æ€§ç´°èŒå¼•èµ·ä¹‹æ„ŸæŸ“ç—‡ |
| è¡›ç½²è—¥è£½å­—ç¬¬009099è™Ÿ | ä¼Šå…‹å®šè† å›Š250æ¯«å…‹ | è† å›ŠåŠ‘ | è‘¡è„çƒèŒã€éˆçƒèŒã€è‚ºç‚é›™çƒèŒã€è…¦è†œç‚çƒèŒåŠå…¶ä»–å…·æœ‰æ„Ÿå—æ€§ç´°èŒå¼•èµ·ä¹‹æ„ŸæŸ“ç—‡ |
| è¡›ç½²è—¥é™¸è¼¸å­—ç¬¬000404è™Ÿ | é ­å­¢åŠ›æ¬£ | ï¼ˆç²‰ï¼‰ | æŠ—ç”Ÿç´  |
| è¡›éƒ¨è—¥é™¸è¼¸å­—ç¬¬001200è™Ÿ | é ­å­¢åŠ›æ¬£å–®æ°´åˆç‰© | ï¼ˆç²‰ï¼‰ | æŠ—ç”Ÿç´  |

**æ³¨æ„**ï¼šå°ç£æœ‰å¤šå®¶å» å•†ç”Ÿç”¢ cephalexin è£½åŠ‘ï¼Œç¸½è¨±å¯è­‰æ•¸é” 313 å¼µï¼Œé¡¯ç¤ºæ­¤è—¥ç‰©åœ¨è‡¨åºŠä¸Šçš„å»£æ³›ä½¿ç”¨ã€‚

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦èª**ï¼š
- å° cephalosporin é¡è—¥ç‰©éæ•è€…ç¦ç”¨
- é’é»´ç´ éæ•è€…å¯èƒ½æœ‰äº¤å‰éæ•åæ‡‰ï¼ˆç´„ 1-5%ï¼‰
- å¯èƒ½å¼•èµ·èƒƒè…¸é“ä¸é©ï¼ˆè…¹ç€‰ã€å™å¿ƒã€å˜”åï¼‰
- é•·æœŸä½¿ç”¨å¯èƒ½å°è‡´èŒç¾¤å¤±èª¿æˆ–äºŒé‡æ„ŸæŸ“

**è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
- èˆ‡ Metforminï¼ˆModerateï¼‰ï¼šCephalexin å¯èƒ½å¢åŠ  metformin è¡€ä¸­æ¿ƒåº¦ï¼Œå¢åŠ ä¹³é…¸ä¸­æ¯’é¢¨éšª
- èˆ‡ Balsalazideï¼ˆModerateï¼‰ï¼šå¯èƒ½å½±éŸ¿ balsalazide çš„ä»£è¬
- èˆ‡ Picosulfuric acidï¼ˆModerateï¼‰ï¼šå¯èƒ½é™ä½ç€‰è—¥æ•ˆæœ
- èˆ‡ Warfarinï¼ˆéœ€ç›£æ¸¬ï¼‰ï¼šå¯èƒ½å½±éŸ¿å‡è¡€åŠŸèƒ½
- å¤šç¨®è—¥ç‰©å…·æœ‰æœªçŸ¥ç­‰ç´šäº¤äº’ä½œç”¨ï¼ˆå¦‚ Calcitriolã€Pantoprazoleã€Doxycyclineã€Morphineã€Omeprazole ç­‰ï¼‰

**ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …**ï¼š
- è…åŠŸèƒ½ä¸å…¨ï¼šéœ€æ ¹æ“šè‚Œé…¸é…æ¸…é™¤ç‡èª¿æ•´åŠ‘é‡
- å¦Šå¨ åˆ†ç´š B é¡ï¼šå‹•ç‰©ç ”ç©¶æœªé¡¯ç¤ºèƒå…’é¢¨éšªï¼Œä½†äººé¡ç ”ç©¶æ•¸æ“šæœ‰é™
- å“ºä¹³æœŸï¼šå¯åˆ†æ³Œè‡³ä¹³æ±ï¼Œä½†é€šå¸¸èªç‚ºå¯å®‰å…¨ä½¿ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients ...

**Diseases requiring dialysis** ğŸŸ¡ Moderate
- Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemo...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients wi...

**ç™²ç™‡ (Epilepsy)** ğŸŸ¡ Moderate
- Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a hi...

**Colitis** ğŸŸ¢ Minor
- Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomy...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
ç›®å‰ç„¡æ–°é©æ‡‰ç—‡é æ¸¬ã€‚Cephalexin ä½œç‚ºç¶“å…¸çš„ç¬¬ä¸€ä»£é ­å­¢é»´ç´ æŠ—ç”Ÿç´ ï¼Œå…¶è‡¨åºŠå®šä½æ¸…æ™°ï¼Œä¸»è¦ç”¨æ–¼æ•æ„Ÿç´°èŒå¼•èµ·çš„æ„ŸæŸ“ç—‡ã€‚åœ¨æ²’æœ‰æ–°çš„é æ¸¬é©æ‡‰ç—‡çš„æƒ…æ³ä¸‹ï¼Œæ‡‰ç¹¼çºŒåœ¨ç¾æœ‰æ ¸å‡†ç¯„åœå…§ä½¿ç”¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç¶­æŒç¾æœ‰é©æ‡‰ç—‡çš„è‡¨åºŠä½¿ç”¨
- æŒçºŒç›£æ¸¬æŠ—è—¥æ€§è®ŠåŒ–
- é—œæ³¨æŠ—ç”Ÿç´ ç®¡ç†åŸå‰‡ï¼ˆAntimicrobial Stewardshipï¼‰
- è‹¥æœ‰æ–°çš„ç ”ç©¶ç™¼ç¾ï¼Œå¯é‡æ–°è©•ä¼°æ½›åœ¨æ–°ç”¨é€”


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Milrinone]({{ "/drugs/milrinone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Benzylpenicillin]({{ "/drugs/benzylpenicillin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamerazine]({{ "/drugs/sulfamerazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Vigabatrin]({{ "/drugs/vigabatrin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Cephalexinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/cephalexin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_cephalexin,
  title = {Cephalexinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/cephalexin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
